The role of intravenous iron in anemia management and transfusion avoidance. (opent nieuw venster)

Auerbach M, Goodnough LT, Picard D, Maniatis A.

Bron‎: Transfusion 2008;48(5):988-1000.

Geïndexeerd‎: PubMed 18346021

DOI‎: 10.1111/j.1537-2995.2007.01633.x

https://www.ncbi.nlm.nih.gov/pubmed/18346021 (opent nieuw venster)

The short-term use of erythropoetin-stimulating agents: impact on the biochemical recurrence of prostate cancer. (opent nieuw venster)

Djavan B, Laze J, Eckersberger E, Finkelstein J, Agalliu I, Lepor H.

Bron‎: BJU Int 2011;108(10):1582-7.

Geïndexeerd‎: PubMed 21443653

DOI‎: 10.1111/j.1464-410X.2011.10173.x

https://www.ncbi.nlm.nih.gov/pubmed/21443653 (opent nieuw venster)

The preoperative use of erythropoietin stimulating proteins prior to radical prostatectomy is not associated with increased cardiovascular or thromboembolic morbidity or mortality. (opent nieuw venster)

Lepor H, Lipkin M, Slova D.

Bron‎: Urology 2010;75(6):1424-8.

Geïndexeerd‎: PubMed 20513505

DOI‎: 10.1016/j.urology.2009.06.095

https://www.ncbi.nlm.nih.gov/pubmed/20513505 (opent nieuw venster)

Comparison of two different doses of preoperative recombinant erythropoietin in men undergoing radical retropubic prostatectomy. (opent nieuw venster)

Nieder AM, Rosenblum N, Lepor H.

Bron‎: Urology 2001;57(4):737-41.

Geïndexeerd‎: PubMed 11306393

https://www.ncbi.nlm.nih.gov/pubmed/11306393 (opent nieuw venster)